Comparison of Cytotoxicity of Mononucleoside Phosphotriester Derivatives Bearing Biolabile Phosphate Protecting Groups in Normal Human Bone Marrow Progenitor Cells
Free accessResearch articleFirst published online December, 1996
Comparison of Cytotoxicity of Mononucleoside Phosphotriester Derivatives Bearing Biolabile Phosphate Protecting Groups in Normal Human Bone Marrow Progenitor Cells
The effects of three mononucleoside phosphotriester derivatives of 3′-azido-2′,3′-dideoxythymidine (AZT) which incorporate biolabile phosphate protecting groups, namely S-acetyl-2-thioethyl (MeSATE), S-(2-hydroxyethylsulfidyl)-2-thioethyl (DTE), and pivaloyloxymethyl (POM) were studied and compared to their nucleoside parent in human myeloid colony-forming cells. Moreover, the relative antiviral potency of these three pronucleotides were determined in primary human peripheral blood mononuclear cells infected with human immunodeficiency virus type 1. The results indicate that the SATE and DTE pro-moieties, as well as their degradation products, do not induce additional toxicity. The bis(MeSATE) phosphotriester derivative of AZT emerged as the most selective inhibitor with an in-vitro therapeutic index of the same order of magnitude as observed for AZT. This study has been extended to the corresponding bis(MeSATE) and bis(DTE) phosphotriester derivatives of 2′,3′-dideoxyuridine (ddU).
AlexanderP., and HolyA. (1994) Prodrugs of analogs of nucleic acid components. Collect Czech Chem Commun59: 2127–2165.
2.
BabaM.PauwelsR.HerdewijnP.De ClercqE.DesmyterJ., and VandeputteM. (1987) Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun142: 128–134.
3.
BalzariniJ. (1994) Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm World Sci16: 113–126.
4.
BalzariniJ.KangG.J.DalaiM.HerdewijnP.De ClercqE.BroderS., and JohnsD.G. (1987) The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides: a comparison with their parental 2′,3′-dideoxyribonucleosides. Mol Pharmacol32: 162–167.
5.
BalzariniJ.BabaM.PauwelsR.HerdewijnP., and De ClercqE. (1988) Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem Pharmacol37: 2847–2856.
6.
ChuC.K.SchinaziR.F.ArnoldB.H.CannonD.L.DoboszewskiB.BhadtiV.B., and GuZ. (1988) Comparative activity of 2′,3′-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells. Biochem Pharmacol37: 3543–3548.
7.
De ClercqE. (1992) HIV inhibitors targeted at the reverse transcriptase. AIDS Res Human Retrov8: 119–134.
8.
De FloraA.ZocchiE.GuidaL.PolvaniC., and BenattiU. (1988) Conversion of encapsulated 5-fluoro-2′-deoxyuridine 5′-monophosphate to the antineoplastic drug 5-fluoro-2′-deoxyuridine in human erythrocytes. Proc Natl Acad Sci USA85: 3145–3149.
9.
FrickL.W.NelsonD.J.St ClairM.H.FurmanP.A., and KrenitskyT.A. (1988) Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem Biophys Res Commun154: 124–129.
10.
FridlandA.ConnellyM.C., and AshmunR. (1990) Relation of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3′-azido-3′-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol Pharmacol37: 665–670.
11.
FurmanP.A., and BarryD.W. (1988) Spectrum of antiviral activity and mechanism of action of Zidovudine. Am J Med85: 176–181.
12.
FurmanP.A.FyfeJ.A.St ClairM.H.WeinholdK.RideoutJ.L.FreemanG.A.LehrmanS. NusinoffBolognesiD.P.BroderS.MitsuyaH., and BarryD.W. (1986) Phosphorylation of 3′-azidothymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA83: 8333–8337.
13.
GaoW.Y.AgbariaR.DriscollJ.S., and MitsuyaH. (1994) Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem259: 12633–12638; and references cited therein.
14.
GirardetJ.-L.PérigaudC.AubertinA.-M.GosselinG.KirnA.ImbachJ.-L. (1995) Increase of the anti-HIV activity of d4T in human T-cell culture by the use of the SATE pronucleotide approach. Bioorg Med Chem Lett5: 2981–2984.
15.
GosselinG., and ImbachJ.-L. (1993) The anti-HIV nucleoside phosphotriester approach: controversial comments and complementary data. Int Antiviral News1: 100–102.
16.
HaoZ.FarquharD.De VicoA.L.SarngadharanM.G.CooneyD.A., and JohnsD.G. (1988) 2′,3′-Dideoxyuridine triphosphate: a potent inhibitor of HIV reverse transcriptaseProc Am Assoc Cancer Res29: 348.
17.
HaoZ.CooneyD.A.FarquharD.PernoC.F.ZhangK.MasoodR.WilsonY.HartmanN.R.BalzariniJ., and JohnsD.G. (1990) Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxyuridine-5′-triphosphateMol Pharmacol37: 157–163.
18.
HarringtonJ.A.MillerW.H., and SpectorT. (1987) Effector studies of 3′-azidothymidine nucleotides with human ribonucleotide reductase. Biochem Pharmacol36: 3757–3761.
19.
JonesR.J., and BischofbergerN. (1995) Minireview: nucleotide prodrugs. Antiviral Res27: 1–17.
20.
KernE.R. (1990) Preclinical evaluation of antiviral agents: in vitro and animal model testing. In: Antiviral Agents and Viral Diseases of Man. GalassoG.J.WhitleyR.J., and MeriganT.C. (eds). New York: Raven Press, pp. 87–123.
21.
LefebvreI.PérigaudC.PomponA.AubertinA.-M.GirardetJ.-L.KirnA.GosselinG., and ImbachJ.-L. (1995) Mononucieoside phosphotriester derivatives with Sacyl-2-thioethyl bioreversible phosphate protecting groups. In tracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate (AZTMP). J Med Chem38: 3941–3950.
22.
LeibmanK.C., and HeidebergC. (1955) The metabolism of 32P-labeled ribonucleotides in tissue slices and cell suspensions. J Biol Chem216: 823–830.
23.
LichtensteinJ.BarnerH.D., and CohenS.S. (1960) The metabolism of exogenously supplied nucleotides by Escherichia coli. J Biol Chem235: 457–465.
24.
MagnaniM.BianchiM.RossiL., and StocchiV. (1989) Human red blood cells as bioreactors for the release of 2′,3′-dideoxycytidine, an inhibitor of HIV infectivity. Biochem Biophys Res Commun164: 446–452.
25.
NilssonS.ReichardP., and SkoogL. (1980) Deoxyuridine triphosphate pools after polyoma virus infection. J Biol Chem255: 9552–9555.
26.
OhmoriH., and YamamotoI. (1983) Mechanism of augmentation of the antibody response in vitro by 2-mercaptoethanol in murine lymphocytes. Cell Immunol79: 173–185.
27.
PérigaudC.GosselinG.LefebvreI.GirardetJ.-L.BenzariaS.BarberI., and ImbachJ.-L. (1993) Rational design for cytosolic delivery of nucleoside monophosphates: « SATE » and « DTE » as enzyme-labile transient phosphate protecting groups. Bioorg Med Chem Lett3: 2521–2526.
28.
PérigaudC.AubertinA.-M.BenzariaS.PelicanoH.GirardetJ.-L.MauryG.GosselinG.KirnA., and ImbachJ.-L. (1994) Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis (SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine. Biochem Pharmacol48: 11–14.
29.
PérigaudC.GirardetJ.-L.GosselinG., and ImbachJ.-L. (1995) Comments on nucleotide delivery forms. In: Advances in Antiviral Drug Design. De ClercqE. (ed.). Greenwich: JAI Press In c., pp. 147–172.
30.
PomponA.LefebvreI.ImbachJ.-L.KahnS., and FarquharD. (1994) Decomposition pathways of the monoand bis (pivaloyloxymethyl) esters of azidothymidine 5′-monophosphate in cell extract and in tissue culture medium: an application of the ‘on-line ISRP-cleaning’ HPLC technique. Antiviral Chem Chemother5: 91–98.
31.
PuechF.GosselinG.LefebvreI.PomponA.AubertinA.-M.KirnA., and ImbachJ.-L. (1993) In tracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. Antiviral Res22: 155–174.
32.
RattoG.M.PayneR.OwenW.G., and TsienR.Y. (1988) The concentration of cytosolic free calcium in vertebrate rod outer segments measured with Fura-2. J Neurosci8: 3240–3246.
33.
RollP.M.WeinfeldH.CarollE., and BrownG.B. (1956) The utilisation of nucleotides by the mammal. IV. Triply labeled purine nucleotides. J Biol Chem220: 439–454.
34.
SastryJ.K.NeheteP.N.KhanS.NowakB.J.PlunkettW.ArlinghausR.B., and FarquharD. (1991) Membrane-permeable dideoxyuridine 5′-monophosphate analogue inhibits human immunodeficiency virus infection. Mol Pharmacol41: 441–445.
35.
ShimizuS.I.BalzariniJ.De ClercqE., and WalkerR.T. (1992) The synthesis and biological properties of some aryl bis (nucleosid-5′-yl) phosphates using nucleosides with proven anti-HIV activity. Nucleosides & Nucleotides11: 583–594.
SommadossiJ.-P., and CarlisleR. (1987) Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother31: 452–454.
38.
SommadossiJ.-P.CarlisleR.SchinaziR.F., and ZhouZ. (1988) Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother32: 997–1001.
39.
TiffertT.Garcia-SanchoJ., and LewV.L. (1984) Irreversible depletion caused by low concentrations of formaldehyde and of calcium-chelator esters in intact human red cells. Biochim Biophys Acta773: 143–156.
40.
TsienR., and PozzanT. (1989) Measurement of cytosolic free Ca2+ with Quin2. Methods Enzymol172: 230–262.
41.
ZelphatiO.DegolsG.LoughreyH.LesermanL.PomponA.PuechF.MaggioA.-F.ImbachJ.-L., and GosselinG. (1993) Inhibition of HIV-1 replication in cultured cells with phosphorylated dideoxyuridine derivatives encapsulated in immunoliposomes. Antiviral Res21: 181–195.
